Videos

Dosing Lenvatinib for First-Line Renal Cell Carcinoma Treatment

Kidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Thomas Powles, MBBS, MD, MRCP

Treating Favorable Risk Patients with Renal Cell Carcinoma with Lenvatinib

An explanation of dosing strategies when treating patients with renal cell carcinoma in the first-line with lenvatinib.

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

Risk Factors in the Management of Advanced Renal Cell Carcinoma

Experts discuss the safety of treating renal cell carcinoma with lenvatinib within different patient risk populations.

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

Treatment Options in RAI-refractory DTC in Second Line and Beyond

Possible comorbidities and other risk factors in advanced renal cell carcinoma that would affect potential treatment regimens.

$Treatment Options in RAI-refractory DTC in Second Line and Beyond$

Lori Wirth, MD;Matthew Fowler

CAR-T Therapies in Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 and KarMMA Studies

Lori Wirth, MD, discusses the role of cabozantinib in the second-line setting for patients with radioiodine-refractory differentiated thyroid cancer and reviews the results from the COSMIC-311 trial.

$CAR-T Therapies in Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 and KarMMA Studies$

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

BCMA-Targeting Bispecific Agents for Relapsed/Refractory Multiple Myeloma Treatment

Key takeaways from the CARTITUDE-1 study and the KarMMA study evaluating CAR T-cell therapies for relapsed/refractory multiple myeloma.

$BCMA-Targeting Bispecific Agents for Relapsed/Refractory Multiple Myeloma Treatment$

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

Novel BCMA-Targeting Agents for the Treatment of Relapsed/Refractory Multiple Myeloma

An overview of BCMA-targeting bispecific agents in development for multiple myeloma, including talquetamab and teclistamab.

$Novel BCMA-Targeting Agents for the Treatment of Relapsed/Refractory Multiple Myeloma$

Rafael Fonseca, MD;Krina K. Patel, MD;Caitlin Costello, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

Outcomes with Daratumumab in Frontline Versus Subsequent Lines of Therapy in Transplant-Ineligible MM

A panel of doctors discuss the available treatment options for early and late relapsed multiple myeloma, including approved novel BCMA-targeting agents.

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

Marina Frimer, MD, Talks Future Treatments in Uterine Cancer

A look at the patient outcomes with daratumumab use in the frontline vs second-line setting in patients with transplant-ineligible multiple myeloma, and the pros and cons of subcutaneous vs intravenous daratumumab.

Marina Frimer, MD

Patients Suitable for First-Line, Single-Agent Therapy and NCCN-Recommended Regimens

Marina Frimer, MD, spoke about what the future holds for the treatment of patients with platinum-sensitive recurrent uterine cancer.

David Aggen, MD, PhD;Robert S. Alter, MD;Arnab Basu, MD, MPH, FACP

Evolution of Combination Therapy As The Standard of Care

David Aggen, MD, PhD identifies patient populations who may benefit from single-agent therapy and reviews NCCN recommendations for first-line treatment of metastatic clear cell RCC.

David Aggen, MD, PhD;Robert S. Alter, MD;Arnab Basu, MD, MPH, FACP

Sam Klempner, MD, Discusses Minimal Residual Disease in Gastrointestinal Cancers

Robert Alter, MD, weighs in on the evolution of combination therapy as the first-line standard of care for patients with metastatic clear cell RCC.

Sam Klempner, MD

Newer First-Line Combination Therapy Options

Sam Klempner, MD, spoke about the importance of expanding minimal residual disease platforms for patients with gastrointestinal cancers.

Robert S. Alter, MD;David Aggen, MD, PhD;Arnab Basu, MD, MPH, FACP

Comparison of Older First-Line, Single-Agent Therapies

David Aggen, MD, PhD touches on the availability of newer first-line combination treatment options for metastatic disease.

David Aggen, MD, PhD;Robert S. Alter, MD;Arnab Basu, MD, MPH, FACP

Treatment Options in the Frontline Setting for Metastatic HER2+ Breast Cancer

Robert Alter, MD compares older, single-agent first line therapies for patients with metastatic clear cell RCC.

Sara Hurvitz, MD;Stefania Maraka, MD;Ruta Rao, MD

Clinical Case Presentation: A 36-Year-Old Woman with Breast Cancer and Brain Metastases

Dr Sara Hurvitz provides an overview of HER2+ breast cancer, and Dr Ruta Rao details the frontline treatment options available for metastatic cases.

Sara Hurvitz, MD;Stefania Maraka, MD;Ruta Rao, MD

PFS With Ixazomib + Pomalidomide and Dexamethasone in RRMM: Upcoming Trial Data

Ruta Rao, MD, presents the case of a 36-year-old woman with metastatic HER2+ breast cancer and brain metastases.

Paul G. Richardson, MD;Cristina Gasparetto, MD

Novel Combination Strategies in the Treatment of Renal Cell Carcinoma

Experts share their excitement for upcoming PFS trial data to be presented on the combination of ixazomib, pomalidomide, and dexamethasone in multiple myeloma.

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

Optimizing RCC Management: Addressing Quality-of-Life Measures and Metastasis

Before closing out their discussion on intermediate-risk RCC, experts review frontline triplet combinations and possible treatment options following relapse after nivolumab-ipilimumab.

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

Brian Slomovitz, MD, Discusses Previous Trials of Pembrolizumab in Endometrial Cancer

Comprehensive discussion on how to best treat patients with renal cell carcinoma and brain or bone metastasis.

Brian Slomovitz, MD

Nicolas Girard, MD, on EFS Findings With Nivolumab and Chemotherapy in Resectable NSCLC

Brian Slomovitz, MD, spoke about previously conducted trials that used regimens involving pembrolizumab and chemotherapy for patients with newly diagnosed high-risk endometrial cancer at SGO 2022.

Nicolas Girard, MD

April 17th 2022

Nicolas Girard, MD, highlighted key findings from the CheckMate 816 trial, examining nivolumab and chemotherapy vs chemotherapy alone in resectable non–small cell lung cancer.

Frederick Locke, MD, Talks Unmet Needs Reduced by Axi-Cel Use in LBCL

Frederick Locke, MD

April 16th 2022

Frederick Lock, MD, spoke about how axicabtagene ciloleucel has improved survival in patients with large B-cell lymphoma.

Gennady Bratslavsky, MD, on Adjuvant Therapy in RCC

Gennady Bratslavsky, MD

Patient Profile: A 73-Year-Old Woman with Post-Cystectomy mUC

Gennady Bratslavsky, MD, spoke about the role of adjuvant therapy in renal cell carcinoma at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

Ira Winer, MD, PhD, on Surprising Findings From ARTISTRY-1 in Ovarian Cancer

Petros Grivas, MD, PhD, introduces a patient profile of a woman with metastatic UC and invites panel members to comment on how they might approach initial treatment and management of the patient.

Ira Winer, MD, PhD, FACOG

Recent Treatment Advances in Urothelial Cancer

Ira Winer, MD, PhD, FACOG, spoke about high response rates observed in patients with pretreated platinum-resistant ovarian cancer from the phase 1/2 ARTISTRY-1 trial.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD